Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting the cannabinoid CB 2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice
Cristina Palomo‐Garo, Yolanda Gómez‐Gálvez, Concepción García, et al.
Pharmacological Research (2016) Vol. 110, pp. 181-192
Closed Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

The Role of Lipids in Parkinson’s Disease
Helena Xicoy, Bé Wieringa, Gerard J.M. Martens
Cells (2019) Vol. 8, Iss. 1, pp. 27-27
Open Access | Times Cited: 204
Endocannabinoid system in neurodegenerative disorders
Balapal S. Basavarajappa, Madhu Shivakumar, Vikram Joshi, et al.
Journal of Neurochemistry (2017) Vol. 142, Iss. 5, pp. 624-648
Open Access | Times Cited: 184
Parkinson’s disease: experimental models and reality
Peizhou Jiang, Dennis W. Dickson
Acta Neuropathologica (2017) Vol. 135, Iss. 1, pp. 13-32
Open Access | Times Cited: 99
CB2 receptor in the CNS: From immune and neuronal modulation to behavior
Wanda Grabon, Sylvain Rheims, Jonathon Smith, et al.
Neuroscience & Biobehavioral Reviews (2023) Vol. 150, pp. 105226-105226
Open Access | Times Cited: 28
Therapeutic applications of cannabinoids
Nancy Maurya, Bharath Kumar Velmurugan
Chemico-Biological Interactions (2018) Vol. 293, pp. 77-88
Closed Access | Times Cited: 70
Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer’s, Parkinson’s, and Huntington’s Diseases
Catalina Pérez-Olives, Rafael Rivas‐Santisteban, Jaume Lillo, et al.
Advances in experimental medicine and biology (2020), pp. 81-92
Closed Access | Times Cited: 43
Neuroprotective effect of engineeredClostridiumbutyricum‐pMTL007‐GLP‐1 on Parkinson's disease mice models via promoting mitophagy
Yun Wang, Wen‐jie Chen, Yiyang Han, et al.
Bioengineering & Translational Medicine (2023) Vol. 8, Iss. 3
Open Access | Times Cited: 16
Targeting LRRK2 in Parkinson’s disease: an update on recent developments
Sharon L. Chan, Eng‐King Tan
Expert Opinion on Therapeutic Targets (2017) Vol. 21, Iss. 6, pp. 601-610
Closed Access | Times Cited: 46
An upconversion nanoplatform based multi-effective theatment for Parkinson’s disease
Binbin Hu, Huaqiang Fang, Zhixin Huang, et al.
Chemical Engineering Journal (2023) Vol. 465, pp. 142959-142959
Closed Access | Times Cited: 13
Cannabinoid receptor as a potential therapeutic target for Parkinson’s Disease
Himadri Shekhaar Baul, Ceera Manikandan, Dwaipayan Sen
Brain Research Bulletin (2019) Vol. 146, pp. 244-252
Closed Access | Times Cited: 31
Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson’s Disease
Sonia Burgaz, Concepción García, María Gómez‐Cañas, et al.
Molecules (2019) Vol. 24, Iss. 15, pp. 2702-2702
Open Access | Times Cited: 31
Investigation in blood-brain barrier integrity and susceptibility to immune cell penetration in a mouse model of Dravet syndrome
Cristina Alonso, Alicia García‐Culebras, Valentina Satta, et al.
Brain Behavior & Immunity - Health (2025) Vol. 44, pp. 100955-100955
Open Access
Environmental Factors Exacerbate Parkinsonian Phenotypes in an Asian-Specific Knock-In LRRK2 Risk Variant in Mice
Zoë Bichler, Sarivin Vanan, Zhiwei Zhang, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 8, pp. 3556-3556
Open Access
Expression of GPR55 and either cannabinoid CB1 or CB2 heteroreceptor complexes in the caudate, putamen, and accumbens nuclei of control, parkinsonian, and dyskinetic non-human primates
Eva Martínez‐Pinilla, Alberto J. Rico, Rafael Rivas‐Santisteban, et al.
Brain Structure and Function (2020) Vol. 225, Iss. 7, pp. 2153-2164
Closed Access | Times Cited: 26
Neuropathological Characterization of a Dravet Syndrome Knock-In Mouse Model Useful for Investigating Cannabinoid Treatments
Valentina Satta, Cristina Alonso, Paula Díez, et al.
Frontiers in Molecular Neuroscience (2021) Vol. 13
Open Access | Times Cited: 21
Disease-modifying effects of cannabidiol, β-caryophyllene and their combination in Syn1-Cre/Scn1aWT/A1783V mice, a preclinical model of Dravet syndrome
Cristina Alonso, Valentina Satta, Inés Hernández-Fisac, et al.
Neuropharmacology (2023) Vol. 237, pp. 109602-109602
Open Access | Times Cited: 8
Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice
Irene Santos‐García, Carmen Rodríguez‐Cueto, Patricia Villegas, et al.
Journal of Neuroinflammation (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 7
Allodynia Lowering Induced by Cannabinoids and Endocannabinoids (ALICE)
Livio Luongo, Katarzyna Starowicz, Sabatino Maione, et al.
Pharmacological Research (2017) Vol. 119, pp. 272-277
Closed Access | Times Cited: 21
Untapped endocannabinoid pharmacological targets: Pipe dream or pipeline?
Jenny L. Wilkerson, Joshua A. Bilbrey, Jasmine S. Felix, et al.
Pharmacology Biochemistry and Behavior (2021) Vol. 206, pp. 173192-173192
Closed Access | Times Cited: 14
Hydroxysafflor yellow A promotes α-synuclein clearance via regulating autophagy in rotenone-induced Parkinson’s disease mice
Bing Han, Lijie Wang, Fenghua Fu, et al.
Folia Neuropathologica (2018) Vol. 56, Iss. 2, pp. 133-140
Open Access | Times Cited: 15
The Role of Cannabinoid Type 2 Receptors in Parkinson’s Disease
Maria Sofia Basile, Emanuela Mazzon
Biomedicines (2022) Vol. 10, Iss. 11, pp. 2986-2986
Open Access | Times Cited: 8
Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome
Cristina Alonso, Valentina Satta, Paula Díez-Gutiérrez, et al.
Neuropharmacology (2021) Vol. 205, pp. 108914-108914
Open Access | Times Cited: 10
Therapeutic Application of Modulators of Endogenous Cannabinoid System in Parkinson’s Disease
Л. Г. Хаспеков, С. Н. Иллариошкин
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8520-8520
Open Access | Times Cited: 1
Effects of cannabinoids in Parkinson’s disease animal models: a systematic review and meta-analysis
Berzenn Urbi, Yunjoo Lee, Ian Hughes, et al.
BMJ Open Science (2022) Vol. 6, Iss. 1
Open Access | Times Cited: 5
Ghrelin and Cannabinoid Functional Interactions Mediated by Ghrelin/CB1 Receptor Heteromers That Are Upregulated in the Striatum From Offspring of Mice Under a High-Fat Diet
Alejandro Lillo, Jaume Lillo, Iu Raïch, et al.
Frontiers in Cellular Neuroscience (2021) Vol. 15
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top